Skin Cancer News
When compared with watchful waiting, CLND did not improve survival outcomes among patients with malignant melanoma who have positive SLNB.
Preliminary findings from CheckMate 238 show treatment with nivolumab significantly prolonged recurrence-free survival compared with ipilimumab in patients with resected stage III/IV melanoma after a minimum 18-month follow-up.
Study authors conducted a study comparing the prognostic and discriminatory ability for survival with the 7th and 8th Editions.
The FDA based its approval on the results of the phase 3 COMBI-AD study.
Sentinel nodes were accurately identified in all 30 patients who underwent WLE.
Improvement in RFS was seen regardless of PD-L1 status.
Grade 3 to 4 adverse events were observed in 54% (19), 16% (4), and 13% (2) of patients in Cohorts A, B, and C, respectively.
One death possibly related to treatment was, however, noted in the combination group.
Researchers randomly assigned 129 patients with previously untreated metastatic uveal melanoma to receive dacarbazine plus selumetinib or placebo.
A 75% reduction in SCC risk was observed among patients in the fluorouracil arm vs the placebo-arm.
Baseline tumor size and PD-L1 status were independently associated with the likelihood of a complete response.
The drug combination was studied in patients with BRAFV600E/K mutations in the phase 3 COMBI-AD study, the results of which led to the FDA's Priority Review designation.
Previous studies have demonstrated that melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.
Four hundred and twenty-seven tanning salons were contacted; 32.7% of contacted salons were non-compliant with their respective state's regulations.
Dabrafenib plus trametinib is the first adjuvant therapy indicated specifically for melanoma with the BRAFV600 mutation.
Researchers evaluated data from 7629 patients with melanoma included in the North Carolina cancer registry to determine relevant variables associated with delayed surgery.
Researchers collected ctDNA samples from patients with varying cancer types to determine whether liquid biopsies may help to predict response to checkpoint inhibition.
Previous studies demonstrated that propranolol may inhibit angiogenesis and migration of cancer cells, leading to a delay in disease progression.
Investigators randomly assigned 870 patients with advanced melanoma who had undergone complete resection to receive trametinib and dabrafenib vs placebo for 1 year.
The randomized phase 3 CheckMate 238 trial evaluated the safety and efficacy of nivolumab vs ipilimumab in the resected stage III/IV melanoma setting.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Resveratrol and Cancer
- Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
- Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
- ARID1A Mutations Might Predict Tumor Response to Immunotherapy
- Global Burden of Myeloma Increasing, Access to Treatments Lacking
- Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer
- Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer
- Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy
- Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer
- Identifying Potential Targets for Companion Diagnostic Tests Using Poly-Ligand Profiling